Cargando…
CDK12 and PAK2 as novel therapeutic targets for human gastric cancer
Background: Gastric cancer remains the second leading cause of cancer-related death, and the third in mortality due to lack of effective therapeutic targets for late stage cancer patients. This study aims to identify potential druggable target biomarkers as potential therapeutic options for patients...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255043/ https://www.ncbi.nlm.nih.gov/pubmed/32483448 http://dx.doi.org/10.7150/thno.46137 |
_version_ | 1783539656748433408 |
---|---|
author | Liu, Hui Shin, Seung Ho Chen, Hanyong Liu, Tingting Li, Zhi Hu, Yamei Liu, Fangfang Zhang, Chengjuan Kim, Dong Joon Liu, Kangdong Dong, Zigang |
author_facet | Liu, Hui Shin, Seung Ho Chen, Hanyong Liu, Tingting Li, Zhi Hu, Yamei Liu, Fangfang Zhang, Chengjuan Kim, Dong Joon Liu, Kangdong Dong, Zigang |
author_sort | Liu, Hui |
collection | PubMed |
description | Background: Gastric cancer remains the second leading cause of cancer-related death, and the third in mortality due to lack of effective therapeutic targets for late stage cancer patients. This study aims to identify potential druggable target biomarkers as potential therapeutic options for patients with gastric cancer. Methods: Immunohistochemistry of human gastric tumor tissues was conducted to determine the expression level of cyclin-dependent kinase 12 (CDK12). Multiple in vitro and in vivo assays such as RNAi, mass spectrometry, computer docking models, kinase assays, cell xenograft NU/NU mouse models (CDXs) and patient-derived xenograft NOD/SCID mouse models (PDXs) were conducted to study the function and molecular interaction of CDK12 with p21 activated kinase 2 (PAK2), as well as to find CDK12 inhibitors as potential treatment options for human gastric cancer. Results: Here we identified that CDK12 is a driver gene in human gastric cancer growth. Mechanistically, CDK12 directly binds to and phosphorylates PAK2 at T134/T169 to activate MAPK signaling pathway. We further identified FDA approved clinical drug procaterol can serve as an effective CDK12 inhibitor, leading to dramatic restriction of cancer cell proliferation and tumor growth in human gastric cancer cells and PDXs. Conclusions: Our data highlight the potential of CDK12/PAK2 as therapeutic targets for patients with gastric cancer, and we propose procaterol treatment as a novel therapeutic strategy for human gastric cancer. |
format | Online Article Text |
id | pubmed-7255043 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-72550432020-05-31 CDK12 and PAK2 as novel therapeutic targets for human gastric cancer Liu, Hui Shin, Seung Ho Chen, Hanyong Liu, Tingting Li, Zhi Hu, Yamei Liu, Fangfang Zhang, Chengjuan Kim, Dong Joon Liu, Kangdong Dong, Zigang Theranostics Research Paper Background: Gastric cancer remains the second leading cause of cancer-related death, and the third in mortality due to lack of effective therapeutic targets for late stage cancer patients. This study aims to identify potential druggable target biomarkers as potential therapeutic options for patients with gastric cancer. Methods: Immunohistochemistry of human gastric tumor tissues was conducted to determine the expression level of cyclin-dependent kinase 12 (CDK12). Multiple in vitro and in vivo assays such as RNAi, mass spectrometry, computer docking models, kinase assays, cell xenograft NU/NU mouse models (CDXs) and patient-derived xenograft NOD/SCID mouse models (PDXs) were conducted to study the function and molecular interaction of CDK12 with p21 activated kinase 2 (PAK2), as well as to find CDK12 inhibitors as potential treatment options for human gastric cancer. Results: Here we identified that CDK12 is a driver gene in human gastric cancer growth. Mechanistically, CDK12 directly binds to and phosphorylates PAK2 at T134/T169 to activate MAPK signaling pathway. We further identified FDA approved clinical drug procaterol can serve as an effective CDK12 inhibitor, leading to dramatic restriction of cancer cell proliferation and tumor growth in human gastric cancer cells and PDXs. Conclusions: Our data highlight the potential of CDK12/PAK2 as therapeutic targets for patients with gastric cancer, and we propose procaterol treatment as a novel therapeutic strategy for human gastric cancer. Ivyspring International Publisher 2020-05-15 /pmc/articles/PMC7255043/ /pubmed/32483448 http://dx.doi.org/10.7150/thno.46137 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Liu, Hui Shin, Seung Ho Chen, Hanyong Liu, Tingting Li, Zhi Hu, Yamei Liu, Fangfang Zhang, Chengjuan Kim, Dong Joon Liu, Kangdong Dong, Zigang CDK12 and PAK2 as novel therapeutic targets for human gastric cancer |
title | CDK12 and PAK2 as novel therapeutic targets for human gastric cancer |
title_full | CDK12 and PAK2 as novel therapeutic targets for human gastric cancer |
title_fullStr | CDK12 and PAK2 as novel therapeutic targets for human gastric cancer |
title_full_unstemmed | CDK12 and PAK2 as novel therapeutic targets for human gastric cancer |
title_short | CDK12 and PAK2 as novel therapeutic targets for human gastric cancer |
title_sort | cdk12 and pak2 as novel therapeutic targets for human gastric cancer |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255043/ https://www.ncbi.nlm.nih.gov/pubmed/32483448 http://dx.doi.org/10.7150/thno.46137 |
work_keys_str_mv | AT liuhui cdk12andpak2asnoveltherapeutictargetsforhumangastriccancer AT shinseungho cdk12andpak2asnoveltherapeutictargetsforhumangastriccancer AT chenhanyong cdk12andpak2asnoveltherapeutictargetsforhumangastriccancer AT liutingting cdk12andpak2asnoveltherapeutictargetsforhumangastriccancer AT lizhi cdk12andpak2asnoveltherapeutictargetsforhumangastriccancer AT huyamei cdk12andpak2asnoveltherapeutictargetsforhumangastriccancer AT liufangfang cdk12andpak2asnoveltherapeutictargetsforhumangastriccancer AT zhangchengjuan cdk12andpak2asnoveltherapeutictargetsforhumangastriccancer AT kimdongjoon cdk12andpak2asnoveltherapeutictargetsforhumangastriccancer AT liukangdong cdk12andpak2asnoveltherapeutictargetsforhumangastriccancer AT dongzigang cdk12andpak2asnoveltherapeutictargetsforhumangastriccancer |